Press release
Primary Biliary Cholangitis Treatment Market Driven by Novel Therapeutics and Increasing Diagnostic Accuracy | Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Ipsen Biopharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc.
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With a focus on emerging drug technologies, evolving treatment paradigms, and regulatory frameworks, the report delivers strategic insights to support stakeholders in navigating the rapidly advancing sector from 2025 to 2033.
Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/primary-biliary-cholangitis-treatment-market?ophp
PBC is a chronic autoimmune liver disease that damages bile ducts. The market is growing with approved therapies like ursodeoxycholic acid (UDCA) and obeticholic acid. Pipeline interest is strong, with novel agents targeting FXR receptors, fibrosis, and inflammation gaining traction.
Primary Biliary Cholangitis Treatment Market Competitors Overview:
Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Ipsen Biopharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Glenmark Pharmaceuticals Inc., AbbVie Inc., Aden Healthcare., Zydus Therapeutics Inc., COUR Pharmaceuticals, Kowa Company, Ltd., Mirum Pharma, Parvus Therapeutics Inc, GSK plc., Strides Pharma Science Limited, and Calliditas Therapeutics AB. Among others.
Important Industry Updates of 2024 and 2025:
✅ In February 2025, Gilead Sciences, Inc. announced that the European Commission (EC) had granted conditional marketing authorization for seladelpar for the treatment of Primary Biliary Cholangitis (PBC). This approval allows the use of seladelpar in combination with ursodeoxycholic acid (UDCA) for adults who have had an inadequate response to UDCA alone, or as a monotherapy for those who cannot tolerate UDCA.
Methodology and Scope
The Primary Biliary Cholangitis Treatment Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/primary-biliary-cholangitis-treatment-market?ophp
Primary Biliary Cholangitis Treatment Market Segments Overview:
∎ By Drug Type (Obeticholic Acid, Seladelpar, Elafibranor, Ursodeoxycholic Acid (UDCA), Others)
∎ By Age Group (Adults, Geriatrics)
Regional Overview for Primary Biliary Cholangitis Treatment Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=primary-biliary-cholangitis-treatment-market?ophp
The Report Covers:
➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.
People Also Ask:
➤ What are the current global trends in sales, production, imports, and exports within the «Keyword» market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the «Keyword» market?
Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!"
https://www.datamintelligence.com/reports-subscription
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Biliary Cholangitis Treatment Market Driven by Novel Therapeutics and Increasing Diagnostic Accuracy | Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Ipsen Biopharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc. here
News-ID: 4122123 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
United States Hyperammonemia Market 2025 | Growth Drivers, Trends & Market Forec …
Market Size and Growth
Global Hyperammonemia Market is expected to reach at a Significant CAGR during the forecast period 2024-2031.
Key Development:
United States: Recent Industry Developments
✅ July 2025: Amogy secured an additional $23 million in venture financing, bringing its total funding to $80 million. This investment aims to accelerate the company's growth and advance its ammonia-to-power solutions.
✅ July 2025: Navigator Gas announced a joint venture with Amon Maritime to construct two ammonia-fueled…
United States Internet of Things (IoT) in Agriculture Market 2025 | Growth Drive …
Market Size and Growth
Global Internet of Things (IoT) in Agriculture Market reached US$ 31.10 billion in 2023 and is expected to reach US$ 83.26 billion by 2031, growing with a CAGR of 13.1% during the forecast period 2024-2031.
Recent Mergers and Acquisitions:
United States:
✅ In Sep 2025, Sensei Farms (U.S.), backed by Larry Ellison, acquired ~25 acres in Lockhart, Texas - the former facility of robotics-farming company Iron Ox. While…
United States Medical Device Coatings Market 2025 | Growth Drivers, Key Players …
Market Size and Growth
Medical device coatings market is growing at a High CAGR during the forecast period 2024-2031.
Recent Mergers and Acquisitions:
United States: Recent Medical Device Coatings Developments
✅ In April 2025, the FDA granted 510(k) clearance to Becton Dickinson's CentroVena One central venous catheter, which features an advanced hydrophilic coating to improve device performance.
✅ In March 2025, the U.S. FTC filed suit to block GTCR's planned $627M acquisition of Surmodics…
United States Nephrotic Syndrome Drugs Market 2025 | Growth Drivers, Trends & Ma …
Market Size and Growth
The global nephrotic syndrome drugs market reached US$ 423.7 million in 2023 and is expected to reach US$ 645.3 million by 2030, growing with a CAGR of 5.4% during the forecast period 2024-2031.
Recent Mergers and Acquisitions:
United States:
✅ In June 2025, Biogen initiated a Phase 3 study of felzartamab for the treatment of primary membranous nephropathy, a common cause of nephrotic syndrome. This trial aims to…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
